Join to View Full Profile
15 Parkman StWac 835 Neurology AssociatesBoston, MA 02114
Phone+1 617-726-5532
Fax+1 617-724-1480
Dr. Schwarzschild is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1991 - 1994- Mass General Brigham/Brigham and Women's HospitalInternship, Internal Medicine, 1990 - 1991
Harvard Medical SchoolClass of 1990
Certifications & Licensure
MA State Medical License 1994 - 2025
PA State Medical License 2001 - 2009
American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Safety of Urate Elevation in Parkinson's Disease Start of enrollment: 2009 Jun 01
- Study of Urate Elevation in Parkinson's Disease, Phase 3 Start of enrollment: 2016 Jun 01
- Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials Start of enrollment: 2018 Oct 01
Publications & Presentations
PubMed
- The potential of distributed diagnostics for the early detection of Parkinson's disease.Amit Khanna, James Beck, Kathleen Poston, Michael A Schwarzschild, Graham B Jones
Journal of Parkinson's Disease. 2025-04-17 - GLP-1 agonists to slow down Parkinson's progression? The quest continues.Bastiaan R Bloem, Eric A Macklin, Michael A Schwarzschild
Med. 2025-04-11 - Baseline α-synuclein seeding activity and disease progression in sporadic and genetic Parkinson's disease in the PPMI cohort.Jackson G Schumacher, Xinyuan Zhang, Eric A Macklin, Jian Wang, Armin Bayati
Medrxiv. 2025-04-02
Journal Articles
- Efficacy of Nilotinib in Patients with Moderately Advanced Parkinson DiseaseMichael Schwarzschild, MD, JAMA Neurology
Press Mentions
Antioxidant Fails to Slow Parkinson’s Disease Progression in Clinical TrialSeptember 16th, 2021- Antioxidant Therapy Tested in Early Parkinson’sSeptember 14th, 2021
- NSAIDs Reduce LRRK2 Penetrance in Parkinson's DiseaseSeptember 3rd, 2020
- Join now to see all
Grant Support
- Urate-LRRK2 interactions in Parkinson's diseaseMASSACHUSETTS GENERAL HOSPITAL2019–2025
- Pursuing Purine Pathways To Clinical Trials For Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2009–2012
- Uric Acid:Novel Therapeutic Target For Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2009–2010
- Translational Foundation Of Adenosine Antagonist Use For DyskinesiasNational Institute Of Neurological Disorders And Stroke2006–2010
- Pursuing Purinergic Pathways To Clinical Trials For Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2008
- Targeting Adenosine A2A Receptors In Parkinson'S DiseaseNational Institute Of Neurological Disorders And Stroke2006
- Assess The Efficacy &Safety Of CEP-1347 In PTS W/Early Parkinson'S DiseaseNational Center For Research Resources2004–2006
- A2A Adenosine Receptors In Psychostimulant SensitizationNational Institute On Drug Abuse2001–2005
- Novel Neuroprotection By Caffeine In Parkinson'S DiseaseNational Institute Of Environmental Health Sciences2001–2005
- Translating A2A Receptor Biology Into Novel PD TherapyNational Institute Of Neurological Disorders And Stroke2002
- A2A Adenosine Receptor--A Novel Role In NeuroprotectionNational Institute On Aging2000
- Adenosine A2 Receptors And Psychostimulant InteractionsNational Institute On Drug Abuse1996–1999
- RAS And Neuronal Gene Regulation By CNTFNational Institute Of Neurological Disorders And Stroke1994–1998
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
